Fangyu “Bill” Liu, Ph.D.

President and Chief Executive Officer

With over 20 years of experience, Dr. Liu is an accomplished executive and scientist with a proven track record of building effective teams, technology-based product portfolios and successful pharmaceutical businesses.

Dr. Liu founded Handa Pharmaceuticals in November 2005. Prior to founding Handa, he served as Chief Operating Officer and Vice President of Product Development and Operations at Anchen Pharmaceuticals from September 2002 to August 2005. As its first employee, Dr. Liu helped to set up Anchen’s business operations including formulation development, analytical services, quality assurance, information technology, regulatory affairs and a cGMP facility. Under his direction, the team successfully developed a pipeline of Paragraph IV controlled-release generic products, two of which were first-to-file.

Prior to joining Anchen, Dr. Liu served in various management positions in product development and business development at Yamanouchi Pharma Technologies, where he developed and commercialized Benadryl® FastMelt Orally Disintegrating Tablets, among other proprietary products. From 1992 to 1997, Dr. Liu was employed by Impax Pharmaceuticals, Watson Pharmaceuticals, and Southern Research Institute, where he was credited with the development of several generic controlled-release products.

Dr. Liu received a B.S. degree in Pharmacy from China Pharmaceutical University in 1983 and a Ph.D. degree in Industrial and Physical Pharmacy from Purdue University in 1992.

Meifang “Maggie” Chang, Ph.D.

Senior Vice President – Quality Affairs

Dr. Chang has over 20 years of experience in quality assurance and quality control, Good Laboratory Practices and Good Manufacturing Practices compliance and oversight, analytical methods development, regulatory submissions, and management of clinical production and testing.

Prior to joining Handa, Dr. Chang served as Vice President of Quality Affairs at Anchen Pharmaceuticals. While at Anchen, she worked on numerous development projects which resulted in ANDA regulatory submissions, including the company’s first ANDA, which received FDA approval in November 2005. From 1996 to 2002, Dr. Chang held various management positions in the R&D Analytical Department at Impax Laboratories. She possesses extensive experience in quality issues associated with laboratory and material management, including controlled substances. Dr. Chang received a B.S. degree in Pharmacy from National Taiwan University in 1989 and a Ph.D. degree in Industrial and Physical Pharmacy from Purdue University in 1996.

Stephen D. Cary, M.B.A.

Senior Vice President – Business Development and Chief Operating Officer

Mr. Cary has over 20 years of sales, marketing, and business development experience in branded and generic pharmaceutical products and medical devices. Prior to joining Handa, he served as Executive Vice President of Business Development and Co-founder of Cary Pharmaceuticals Inc., a specialty pharmaceutical company based in the Washington, DC area. From 1992-1999, Mr. Cary held various sales and marketing roles at Glaxo Inc. (now GlaxoSmithKline) and was involved in the product launches and line extensions of several key growth products (Ceftin®, Imitrex®, Serevent®, Zantac®, Zofran®, and Zyban®) for the hospital and retail markets, across multiple therapeutic areas including addiction medicine, anti-infectives, CNS, gastrointestinal, and respiratory.

Mr. Cary received a B.B.A. degree in Marketing from the University of Iowa in 1992 and an M.B.A. degree in Management and Entrepreneurship from the University of Maryland in 1999.

Michael He, PhD

Vice President – Product Development

Dr. He has over 20 years of experience in product development, including formulation and process design/optimization, from laboratory to commercial scales.  He’s led tech-transfer and scale-up efforts, as well as process validation and commercialization efforts for Handa since 2009, resulting in several successful ANDA submissions and partner product launches.

Dr. He previously served at UPM Pharmaceuticals as a member of the management team and the lead scientist, successfully managing key client portfolios, including formulating over 25 products ranging from Phase 1 to commercial launch.  Prior to UPM, Dr. He worked in various product development roles of increasing responsibility at Bayer, Nutrilite and Yamanouchi.

Dr. He received a B.S. in Pharmacy from Fudan University (formerly Shanghai Medical University) in 1986.  He later attended the University of Cincinnati, where he earned an M.S. degree in Pharmaceutical Sciences in 1993 and a Ph.D. degree in Industrial Pharmacy in 1997.

Li Qiao, Ph.D.

Vice President – Analytical Services

Dr. Qiao has led the analytical services function for Handa Pharmaceuticals since 2010.  She has over 16 years of experience in the pharmaceutical industry, with an emphasis on program management and analytical services, including method development, transfer, and validation for active ingredients, intermediates, excipients and finished dosage forms.  Previously, Dr. Qiao worked in various roles of increasing responsibility at 3M Company’s Drug Delivery System Division and in the R&D Analytical Department at Impax.

Dr. Qiao received a Bachelor of Science degree from Nanjing Tech University (formerly Nanjing Institute of Chemical Engineering) in 1992, and a Ph.D. degree in Analytical Chemistry from The University of Alabama in 2001.

Shelly Meachum, R.A.C.

Vice President – Regulatory Affairs

Ms. Meachum has led the regulatory efforts for Handa Pharmaceuticals since 2012, leveraging her prior experience as Director of Regulatory Affairs at Catalent Pharma Solutions, where she was a key contributor on Handa’s successful first to file ANDA programs since 2008.

Her prior experiences include leading regulatory departments at Ei, Inc., a Pharmaceutical Solutions Works, Merz USA, Banner Pharmacaps, and Watson Laboratories.  She received her Bachelor of Science degree, with Honor, from Michigan Technological University and has held certifications from the American Society for Clinical Pathologists, the American Society for Quality and the Regulatory Affairs Professional Society.